Telix completes TLX250-CDx (Zircaix) BLA submission for kidney cancer imaging

3 June 2024 - Telix today announces that it has completed the submission of a biologics license application to the ...

Read more →

Telix submits NDA for new prostate cancer imaging agent

27 May 2024 - Telix Pharmaceuticals today announces it has submitted a new drug application to the US FDA for ...

Read more →

Lumicell’s cutting-edge imaging platform receives historic FDA approval to illuminate residual breast cancer

18 April 2024 - Lumisight and Lumicell DVS previously received FDA fast track and breakthrough device designations, respectively. ...

Read more →

TLX101-CDx (Pixclara) granted FDA fast track designation

16 April 2024 - Telix Pharmaceuticals today announces that the US FDA has granted fast track designation for the Company's investigational ...

Read more →

Curium announces submission of the marketing authorisation application for Pylclari, an innovative (18F)-PSMA PET tracer indicated in adults with prostate cancer to Swissmedic

22 February 2024 - Curium announced today that the marketing authorisation application for Pylclari (piflufolastat (18F)) submitted by exclusive Swiss ...

Read more →

Telix submits biologics license application for TLX250-CDx (Zircaix) for imaging of kidney cancer

19 December 2023 - Telix today announces that it has submitted its biologics license application to the United States US FDA ...

Read more →

The European Commission granted marketing authorisation for Vueway (gadopiclenol) in the European Union

11 December 2023 - Vueway is a new, highly stable, macrocyclic gadolinium-based contrast agent (GBCA) for contrast-enhanced magnetic resonance imaging (CE-MRI): ...

Read more →

Vueway (gadopiclenol) receives positive CHMP opinion

12 October 2023 - The CHMP of the EMA recommended approval of the macrocyclic, high relaxivity Vueway (gadopiclenol) in adults ...

Read more →

US FDA grants approval for Technegas

2 October 2023 - Strong pre-existing demand expected to drive sales momentum for an immediate US wide rollout. ...

Read more →

FDA grants first marketing authorisation for a DNA test to assess predisposition for dozens of cancer types

29 September 2023 - Today, the US FDA grantedde novo marketing authorisation for the Invitae Common Hereditary Cancers Panel, ...

Read more →

Biomarker tests for targeted oncology therapies pose tricky regulatory challenges

29 June 2023 - The US FDA recently announced the launch of a year-long pilot programme regarding diagnostic methods within oncology ...

Read more →

Roche receives FDA clearance for additional Alzheimer's disease cerebrospinal fluid assays, supporting timely diagnosis and treatment decision-making

27 June 2023 - The Elecsys tTau/Abeta42 ratio helps clinicians define Alzheimer's disease biologically and expands Roche's Alzheimer's CSF portfolio to ...

Read more →

FDA approves Bayer’s Ultravist (iopromide) injection for contrast-enhanced mammography

23 June 2023 - Ultravist-300, -370 is now the only contrast agent in the US indicated to visualise known or suspected ...

Read more →

US FDA approves Blue Earth Diagnostics’ Posluma (flotufolastat F 18) injection, first radiohybrid PSMA targeted PET imaging agent for prostate cancer

30 May 2023 - Posluma will be commercially available in the United States in early June 2023. ...

Read more →

Lumicell announces FDA acceptance and priority review of new drug application for Lumisight optical imaging agent for breast cancer

22 May 2023 - The system visually highlights cancer that may have otherwise been left behind and is designed to be ...

Read more →